Velzatinib Aims For Future Direct Comparison With Imatinib in GIST

Michael C. Heinrich, MD, of Oregon Health and Science University, discusses the therapeutic potential of velzatinib, an investigational agent designed to overcome the historical challenges of managing gastrointestinal stromal tumors (GIST). A primary clinical differentiator for velzatinib lies in its highly specific mechanism of action. Although the standard first-line agent imatinib has provided a solid foundation for 25 years, subsequent lines of therapy including sunitinib (Sutent), regorafenib (Stivarga), and ripretinib (Qinlock) all possess off-target affinity that inhibits vascular endothelial growth factor receptors (VEGFR). This broad antagonism induces distinct, often debilitating toxicities, such as palmar-plantar erythrodysesthesia, severe hypertension, and mucositis. Velzatinib, conversely, does not antagonize VEGFR, sparing patients from these common, quality-of-life-limiting adverse events.

Because of its superior overall tolerability profile, velzatinib is transitioning into a frontline study to compete directly against imatinib. Heinrich highlights that previous later-line therapies were rarely advanced to the frontline setting because their toxicity profiles could not rival imatinib’s long-term safety record. Frontline therapy demands an exceptionally high bar for tolerability; given that modern patients routinely experience a median progression-free survival (PFS) of 3 years on imatinib, a comparative agent must be safe enough for individuals to remain on continuous treatment for half a decade or longer.

From a resistance standpoint, the underlying biology of KIT mutations dictates how patients eventually escape imatinib therapy. Velzatinib has been engineered to block almost the entire spectrum of these known secondary resistance mutations, with the exception of one extremely rare, uncommon variant.

A large-scale frontline study will be initiated following favorable first and second-line findings, but the trial is estimated to take 5 to 6 years to demonstrate PFS difference from imatinib. The drug is expected to prolong PFS and meet the safety and efficacy standards required for regulatory approval in the United States and other regions, although Heinrich cautions that the cost of velzatinib vs imatinib could limit its adoption by some healthcare systems.